<DOC>
	<DOCNO>NCT00138138</DOCNO>
	<brief_summary>Fatigue one common symptom prostate cancer . Fatigue lack energy make hard thing normally every day . Some symptom fatigue : - feeling tired and/or weak ; - less interest activity ; - trouble concentrating ; - feeling `` '' ; - feeling exhaust clear reason . There many drug helpful treat fatigue . However , one group medication seem useful . In study , , investigator Memorial Sloan-Kettering Cancer Center , use psychostimulant call Ritalin . The aim study see drug helpful treat fatigue prostate cancer . We also study side effect medication .</brief_summary>
	<brief_title>Psychostimulants Fatigue Prostate Cancer</brief_title>
	<detailed_description>This study open men prostate cancer report feel fatigue . We examine impact psychostimulant treatment depressive symptom severity , neuropsychological test performance , overall quality life , well compare frequency severity treatment associate adverse side effect . We conduct six-week , randomize , double-blind , placebo-controlled , parallel design trial , evaluate relative benefit risk methylphenidate , ( psychostimulant medication ) . Medication give twice daily dosage ( 8 noon ) titrate one capsule every 2-3 day need treat fatigue tolerate . Patients examine regularly safety . We monitor vital sign response medication . This study first kind evaluate pharmacologic intervention fatigue cancer patient utilizes novel psychotropic agent ( psychostimulant ) , assess outcome measure fatigue , well side effect , psychological distress , depression overall quality life . Objectives : To study efficacy methylphenidate vs. placebo treatment fatigue ambulatory men prostate cancer . To study frequency severity adverse side effect associate psychostimulant drug . To study effect psychostimulant treatment fatigue related domains psychosocial function quality life .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>18 year age old English speaking ( patient read offer assistance consent form survey ) . There maximum age cut eligibility study . Diagnosed prostate cancer . Receiving ambulatory medical care time initial assessment primary treat physician aware agree subject 's participation study . Fatigue persistent ( chronicrecurrent continuous period least 2 week ) , report intensity moderate severe ( score 4 great one question assess fatigue two week period 010 numeric rating scale ) . Patients already receive six week Procrit therapy 60,000 unit anemia still significant fatigue become eligible stimulant trial . Patients receive three week thyroid supplementation therapy hypothyroidism still significant fatigue become eligible stimulant trial . Patients able give inform consent . Significant cognitive impairment ( MiniMental Status score 22 ) psychiatric disturbance sufficient , investigator 's judgment , preclude data collection inform consent . Evidence severe renal hepatic disease ; serum creatinine liver function test ( LFT 's ) must high 2 time upper limit normal . A white blood cell count 2,000 cell per cubic millimeter platelet 60,000 per cubic millimeter less . Uncontrolled hypertension ( blood pressure [ BP ] 170/100 great ) exclude patient study . For patient history control hypertension ( either diet medication ) , methylphenidate may increase rest blood pressure 5 mmHg . ( The patient blood pressure , pulse vital sign monitor weekly auspex Genitourinary Clinic , home instruction research nurse , use blood pressure monitor issue study . ) Urgent need primary medical therapy fatigue would appropriate study drug ( eg , severe anemia hemoglobin le 11.0 patient symptomatic . Patients already receive six week Procrit therapy still significant fatigue become eligible trial ) . Patients find significant hypothyroidism ( define thyroid stimulate hormone test great 4.42 upon blood chemistry screen ) , ineligible study complete three week appropriate thyroid supplementation still find exhibit significant fatigue . History substance abuse ( ie , stimulant drug , cocaine , injection drug use ) participation methadone maintenance program . Patients history alcohol abuse exclude study currently abuse alcohol . Meeting criterion diagnosis major depressive episode current ( screen major depression complete use Structured Clinical Interview DSMIIIR , Nonpatient Version [ SCIDNP ] ) . Concurrent use monoamine oxidase ( MAO ) inhibitor , tricyclic antidepressant , psychostimulant exclude subject study participation . Concurrent use antidepressant medication ( eg , selective serotonin reuptake inhibitor [ SSRIs ] , serotoninnorepinephrine reuptake inhibitor [ SNRIs ] ) exclude subject study participation . History allergy , intolerance , methylphenidate . Karnofsky Patient Performance Rating score 50 .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>